| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $679K | — | -85.6% |
| SG&A Expense | $1.3M | — | +280.7% |
| Operating Income | -$2.0M | — | +61.2% |
| Net Income | -$2.5M | — | +49.6% |
| EPS (Basic) | -$0.05 | — | +54.5% |
| EPS (Diluted) | -$0.05 | — | +54.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.1M | -40.1% | — |
| Current Assets | $3.5M | -32.3% | — |
| Total Assets | $3.5M | -32.3% | — |
| Current Liabilities | $1.0M | +67.6% | — |
| Total Liabilities | $1.0M | +67.6% | — |
| Stockholders' Equity | $2.5M | -45.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.1M | — | -191.0% |
| Financing Cash Flow | $250K | — | +0.0% |